Taysha Gene Therapies (TSHA) Other Operating Expenses (2022 - 2026)

Taysha Gene Therapies has reported Other Operating Expenses for 6 years, with the latest figure at $83.4 million in Q4 2025.

• Quarterly Other Operating Expenses rose 28.31% year-over-year to $83.4 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $83.4 million (up 19.42% YoY) and the FY2025 annual result came in at $83.4 million, up 19.42% from the prior year.
• Other Operating Expenses improved to $83.4 million in Q4 2025 per TSHA's latest filing, from $65.0 million in the prior quarter.
• Over five years, Other Operating Expenses peaked at $128.9 million in Q4 2021 and troughed at $616000.0 in Q3 2023.
• A 5-year average of $57.2 million and a median of $65.0 million in 2024 frame the typical range for Other Operating Expenses.
• The sharpest annual moves came in 2022 and 2024: Other Operating Expenses slumped 71.75% in 2022, then soared 685.39% in 2024.
• Over 5 years, Other Operating Expenses stood at $128.9 million in 2021, then plunged by 71.75% to $36.4 million in 2022, then soared by 122.88% to $81.2 million in 2023, then decreased by 19.92% to $65.0 million in 2024, then advanced by 28.31% to $83.4 million in 2025.
• According to Business Quant data, Other Operating Expenses over the past three periods registered $83.4 million, $65.0 million, and $4.8 million for Q4 2025, Q4 2024, and Q3 2024 respectively.